-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Lexeo Therapeutics, Lowers Price Target to $20

Benzinga·05/13/2025 11:28:01
Listen to the news
Chardan Capital analyst Geulah Livshits maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and lowers the price target from $22 to $20.